Found 21 Enz. Inhib. hit(s) with all data for entry = 6378 TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 1nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 1nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 4nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 4nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 4nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 5nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 5nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 5nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 11nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 12nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 20nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 20nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 26nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 46nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 50nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 55nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 76nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 80nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 85nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 87nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 102nMAssay Description:The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i...More data for this Ligand-Target Pair
